Paradigmenwechsel in der Therapie — Eine kritische Bestandsaufnahme

  • Klaus Lindpaintner

Zusammenfassung

Die bedeutenden Fortschritte in molekularer Biologie und Genetik, die uns die letzten Jahrzehnte gebracht haben, haben vor etwa 30 Jahren zu einem klaren „Paradigmenwechsel“ in der Forschung nach neuen Medikamenten geführt, indem das Primat der Chemie durch das Primat der Biologie abgelöst wurde. Seitdem wird versucht, sich nach biologischen Zielmolekülen zu orientieren und entsprechende Substanzen zu finden, anstatt, wie früher, primär neue Verbindungen zu synthetisieren und sie nachträglich auf ihre möglichen biologischen Effekte zu untersuchen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baselga J, Tripathy D, Mendelsohn J et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744PubMedGoogle Scholar
  2. Bogardus ST, Concato J, Feinstein AR (1999) Clinical epidemiological qualityin molecular genetic research. The need for methodological standards. JAMA 281: 1919–1926Google Scholar
  3. Dewar JC, Wheatley AP, Venn A, Morrison JFJ, Britton J, Hall IP (1998) /32 adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy 28: 442–448Google Scholar
  4. Drazen JM, Yandava CN, DubeL et al. (1999) Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22: 168–170PubMedCrossRefGoogle Scholar
  5. Drysdale CM, McGraw DW, Stack CB et al. (2000) Complex promoter and coding region /12-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97: 10483–10488PubMedCrossRefGoogle Scholar
  6. In KH, Asano K, Beier D et al. (1997) Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 99: 1130–1137PubMedCrossRefGoogle Scholar
  7. Mallal S, Nolan C, Witt C et al. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacovir. Lancet 359: 727–732PubMedCrossRefGoogle Scholar
  8. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R (1997) Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100: 3184–3188PubMedCrossRefGoogle Scholar
  9. McGraw DW, Forbes SL, Kramer LA, Liggett SB (1998) Polymorphisms of the 5’ leader cistron of the human beta2adrenergic receptor regulate receptor expression. J Clin Invest 102: 1927–1932PubMedCrossRefGoogle Scholar
  10. Reihsaus E, Innis M, Maclntyre N, Liggett SB (1993) Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 8: 334–349PubMedCrossRefGoogle Scholar
  11. Tan S, Hall IP, Dewar J, Dow E, Lipworth B (1997) Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 350: 995–999PubMedCrossRefGoogle Scholar
  12. Weber WW, Cronin MT (2000) Pharmacogenetic testing. In: Meyers RA (ed) Encyclopedia of analytical chemistry. Wiley and Sons, ChichesterGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Klaus Lindpaintner

There are no affiliations available

Personalised recommendations